Immune Design Corp (NASDAQ:IMDZ) – Equities researchers at Jefferies Group issued their FY2022 earnings per share estimates for shares of Immune Design in a research note issued on Thursday, March 15th, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft forecasts that the biotechnology company will post earnings of ($0.67) per share for the year. Jefferies Group has a “Buy” rating and a $8.00 price objective on the stock.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.10. The company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.81 million. Immune Design had a negative return on equity of 57.56% and a negative net margin of 720.81%.
A number of other brokerages also recently issued reports on IMDZ. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. Cowen reaffirmed a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.63.
Shares of NASDAQ:IMDZ traded up $0.05 during midday trading on Friday, reaching $3.15. The company’s stock had a trading volume of 232,734 shares, compared to its average volume of 372,608. The company has a market capitalization of $151.59, a price-to-earnings ratio of -1.80 and a beta of 1.90. Immune Design has a fifty-two week low of $2.80 and a fifty-two week high of $13.05.
In other news, major shareholder Leo Guthart purchased 20,000 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were acquired at an average cost of $3.90 per share, with a total value of $78,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.70% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of IMDZ. Bain Capital Public Equity Management LLC increased its holdings in Immune Design by 155.3% during the 4th quarter. Bain Capital Public Equity Management LLC now owns 3,316,769 shares of the biotechnology company’s stock worth $12,935,000 after purchasing an additional 2,017,756 shares in the last quarter. Franklin Resources Inc. increased its holdings in Immune Design by 313.4% during the 4th quarter. Franklin Resources Inc. now owns 3,231,753 shares of the biotechnology company’s stock worth $12,604,000 after purchasing an additional 2,450,000 shares in the last quarter. BlackRock Inc. increased its holdings in Immune Design by 80.1% during the 4th quarter. BlackRock Inc. now owns 1,868,078 shares of the biotechnology company’s stock worth $7,285,000 after purchasing an additional 830,861 shares in the last quarter. BVF Inc. IL bought a new stake in Immune Design during the 4th quarter worth approximately $5,732,000. Finally, Vanguard Group Inc. increased its holdings in Immune Design by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after purchasing an additional 144,408 shares in the last quarter. 53.78% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/jefferies-group-comments-on-immune-design-corps-fy2022-earnings-imdz.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Get a free copy of the Zacks research report on Immune Design (IMDZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.